| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A Case Report of Three Tumefactive Demyelinating Lesions after Initiating Fingolimod and Review of Articles
|
Navardi, S.
|
|
|
26 |
C |
p. 263
|
artikel
|
| 2 |
Adverse psychiatric effects of disease-modifying therapies in multiple Sclerosis: A systematic review
|
Gasim, Majid
|
|
|
26 |
C |
p. 124-156
|
artikel
|
| 3 |
Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Relapsing-remitting Multiple Sclerosis Patients Over 8 Years: Care-MS Ii Follow-up (topaz Study)
|
Alroughani, R.
|
|
|
26 |
C |
p. 258
|
artikel
|
| 4 |
Alemtuzumab Improves Clinical and Radiological Outcomes in Patients with Relapsing-remitting Multiple Sclerosis Over 8 Years: Care-MS I Follow-up (topaz Study)
|
Inshasi, J.S.
|
|
|
26 |
C |
p. 258
|
artikel
|
| 5 |
A Longitudinal Study of JC Virus Serostatus Stability Among Multiple Sclerosis Patients
|
Alroughani, R.
|
|
|
26 |
C |
p. 244
|
artikel
|
| 6 |
A Real-world Comparison of Infection Rate and Lymphocyte Counts Among Relapsing: Remitting Multiple Sclerosis Patients 50 Years or Older Treated with Subcutaneous Interferon Beta-1a Or Dimethyl Fumarate
|
Hayward, B.
|
|
|
26 |
C |
p. 259
|
artikel
|
| 7 |
Assessment of Coping Strategies in Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis Patients
|
Mahdi,
|
|
|
26 |
C |
p. 253-254
|
artikel
|
| 8 |
Assessment of Nutritional Status and Expanded Disability Status Scale in Women with Multiple Sclerosis in Chennai (south India) and the Impact of a Nutrition Education Program
|
Arshia, H.
|
|
|
26 |
C |
p. 253
|
artikel
|
| 9 |
Association of Vitamin D Deficiency in Multiple Sclerosis
|
Alsomali, N.
|
|
|
26 |
C |
p. 243
|
artikel
|
| 10 |
Autoimmune encephalitis with elevated N-type calcium channel antibodies as a multiple sclerosis mimic
|
Frey, Jessica
|
|
|
26 |
C |
p. 201-203
|
artikel
|
| 11 |
B-cell composition in the blood and cerebrospinal fluid of multiple sclerosis patients treated with dimethyl fumarate
|
Høglund, Rune A.
|
|
|
26 |
C |
p. 90-95
|
artikel
|
| 12 |
Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS): Is it Enough for Screening?
|
Moghaddasi, M.
|
|
|
26 |
C |
p. 235
|
artikel
|
| 13 |
Brucellosis Presenting as a Longitudinally Extensive Transverse Myelitis
|
Yamout, B.
|
|
|
26 |
C |
p. 250-251
|
artikel
|
| 14 |
Challenges in the Diagnosis of Primary Progressive Multiple Sclerosis in Egypt
|
Swelam, M.S.
|
|
|
26 |
C |
p. 236
|
artikel
|
| 15 |
Characteristics of Neuromyelitis Optica Spectrum Disorder in a Moroccan Population
|
Bennis, A.
|
|
|
26 |
C |
p. 235
|
artikel
|
| 16 |
Cladribine Tablets 35 mg/kg Is Efficacious in Patients Aged Above and Below 45 Years with Relapsing Multiple Sclerosis in the Clarity Study
|
Giovanonni, G.
|
|
|
26 |
C |
p. 262
|
artikel
|
| 17 |
Clinical Aspects of Multiple Sclerosis: An Observational Study From The Sheikh Khalifa Medical City in Abu Dhabi
|
Mir, R.
|
|
|
26 |
C |
p. 241
|
artikel
|
| 18 |
Clinical Efficacy Is Sustained in Relapsing Remitting Multiple Sclerosis Following Treatment Switch to Placebo from Cladribine Tablets in Patients with High Disease Activity at Baseline
|
Vermersch, P.
|
|
|
26 |
C |
p. 260
|
artikel
|
| 19 |
Clinical utility of anti-MOG antibody testing in a Danish cohort
|
Papp, Viktoria
|
|
|
26 |
C |
p. 61-67
|
artikel
|
| 20 |
Cognitive and Psychiatric Events in Multiple Sclerosis: Could they Be the First Signs?
|
Bouhamed, A.
|
|
|
26 |
C |
p. 236
|
artikel
|
| 21 |
Comparing MS Related Quality of Life in Patients with and Without Relapse by Means of Perception De La Scle'rose En Plaques Et De Ses Pousse'es Questionnaire
|
Ghajarzadeh, M.
|
|
|
26 |
C |
p. 254
|
artikel
|
| 22 |
Comparing Patient and Healthcare Professional Perceptions on Multiple Sclerosis Management and Care: A Sub-analysis of Disease Progression Perspectives
|
Rieckmann, P.
|
|
|
26 |
C |
p. 252-253
|
artikel
|
| 23 |
Considerations for using Natalizumab treatment in patients with a history of choroidal melanoma
|
Kaye, Abigail E.
|
|
|
26 |
C |
p. 74-76
|
artikel
|
| 24 |
Depicting Neurogenic Dysphagia in a Sample of Egyptian Multiple Sclerosis Patients
|
Fathi, S.
|
|
|
26 |
C |
p. 237-238
|
artikel
|
| 25 |
Description of Quality of Sleep and Sleep Disorder Among Indonesian Multiple Sclerosis Foundation Members
|
Saputra, G.N.
|
|
|
26 |
C |
p. 242-243
|
artikel
|
| 26 |
Diffusion Tensor Imaging as a Solution to Problematic Brain White Matter Patches
|
Saleh, Alaa
|
|
|
26 |
C |
p. 248
|
artikel
|
| 27 |
Diffusivity Parameters as Markers for NAGM Involvement and Disease Progression in MS Patients: Diffusion Tensor Imaging Study
|
Dahshan, A.
|
|
|
26 |
C |
p. 251
|
artikel
|
| 28 |
Disease Course, Progression and Activity Among Neuromyelitis Optica (NMOSD) Patients Who Treated with Rituximab, 6 and 12 Months After the First Dose, in Isfahan
|
Dastjerdi, R.M.
|
|
|
26 |
C |
p. 262-263
|
artikel
|
| 29 |
Effect of Age on Clinical Outcomes in Patients Treated with Fingolimod: Pooled Analysis of Real-world Phase IV Studies
|
Chitnis, T.
|
|
|
26 |
C |
p. 255
|
artikel
|
| 30 |
Effect of Biotin on Patients with Multiple Sclerosis in a Sample of Egyptian Patients
|
Ali, A.E.
|
|
|
26 |
C |
p. 241-242
|
artikel
|
| 31 |
Effects of Fingolimod on MRI Outcomes in Patients with Pediatric-onset Multiple Sclerosis: Results from the Phase 3 ParadigMS Study
|
Arnold, D.
|
|
|
26 |
C |
p. 255
|
artikel
|
| 32 |
Efficacy and Safety of Continuous Fingolimod Treatment for At Least 5 Years in Patients with Relapsing-remitting Multiple Sclerosis: Analysis of Long-term Data
|
Kappos, L.
|
|
|
26 |
C |
p. 237
|
artikel
|
| 33 |
Efficacy and Safety of Fingolimod in Patients with Multiple Sclerosis
|
Hatem, A.O.
|
|
|
26 |
C |
p. 263
|
artikel
|
| 34 |
Ensemble-plus Study Design: An Investigation of Shortened Ocrelizumab Infusion Time on Infusion-related Reactions in Patients with Relapsing Multiple Sclerosis from the Phase Iiib Ensemble-plus Study
|
Yamout, B.
|
|
|
26 |
C |
p. 256
|
artikel
|
| 35 |
Exploring the role of physical activity and exercise for managing vascular comorbidities in people with multiple sclerosis: A scoping review
|
Ewanchuk, Benjamin W.
|
|
|
26 |
C |
p. 19-32
|
artikel
|
| 36 |
Extreme delta brush and distinctive imaging in a pediatric patient with autoimmune GFAP astrocytopathy
|
Theroux, Liana M.
|
|
|
26 |
C |
p. 121-123
|
artikel
|
| 37 |
Features of Multiple Sclerosis in the Southern and Western Regions of Kazakhstan
|
Meirkhankyzy, S.A.
|
|
|
26 |
C |
p. 241
|
artikel
|
| 38 |
Gadolinium Effect on Subcortical Gray Matter Segmentation in Multiple Sclerosis
|
Hannoun, S.
|
|
|
26 |
C |
p. 250
|
artikel
|
| 39 |
Gadolinium Exposure in Multiple Sclerosis: Evaluation of Unenhanced-t1 Images Signal Intensity Alterations in the Dentate Nucleus and the Globus Pallidus
|
Hannoun, S.
|
|
|
26 |
C |
p. 250
|
artikel
|
| 40 |
Herpes simplex virus encephalitis temporally associated with dimethyl fumarate-induced lymphopenia in a multiple sclerosis patient
|
Perini, Paola
|
|
|
26 |
C |
p. 68-70
|
artikel
|
| 41 |
How does cognition relate to employment in multiple sclerosis? A systematic review
|
Clemens, Laura
|
|
|
26 |
C |
p. 183-191
|
artikel
|
| 42 |
Impact of Gadolinium-enhancing (GD+) Lesions on No Evidence of Disease Activity (NEDA) Status in Subcutaneous Interferon Beta-1a (SC IFNβ-1a)-treated Patients
|
Freedman, M.
|
|
|
26 |
C |
p. 239-240
|
artikel
|
| 43 |
In Clarity the Severity and Frequency of Relapses are Lower in Patients with Relapsing-remitting Multiple Sclerosis Treated with Cladribine Tablets Versus Placebo
|
Schippling, S.
|
|
|
26 |
C |
p. 262
|
artikel
|
| 44 |
Infratentorial and Optic Nerve MS Lesions Enhanced Detection Using 3D Flair MRI
|
El F.Nada, M.A.
|
|
|
26 |
C |
p. 248-249
|
artikel
|
| 45 |
Interplay Between Fatigue and Sleep Disturbances in Patients with Multiple Sclerosis
|
Larnaout, F.
|
|
|
26 |
C |
p. 252
|
artikel
|
| 46 |
Investigating Carbohydrate to Protein Ratio as a Dietary Risk Factor for Neuromyelitis Optica Spectrum Disorder
|
Rezaeimanesh, N.
|
|
|
26 |
C |
p. 245-246
|
artikel
|
| 47 |
Investigating the Effect of Teriflunomide on Diffuse Brain Tissue Damage in the Phase 3 TEMSO Study
|
Sprenger, T.
|
|
|
26 |
C |
p. 258-259
|
artikel
|
| 48 |
Leptomeningeal inflammation in multiple sclerosis: Insights from animal and human studies
|
Wicken, Cassie
|
|
|
26 |
C |
p. 173-182
|
artikel
|
| 49 |
Longer-term Safety with Siponimod Treatment in Multiple Sclerosis: Pooled Analysis of Data from the Bold and Expand Trials and their Extensions
|
Kappos, L.
|
|
|
26 |
C |
p. 255-256
|
artikel
|
| 50 |
Long-term Disease Control with Fingolimod in RRMS Patients with Active Disease
|
Havrdová, E.K.
|
|
|
26 |
C |
p. 236-237
|
artikel
|
| 51 |
Long-term Efficacy and Safety of Teriflunomide: An Analysis of Pooled Clinical Trials
|
Freedman, M.S.
|
|
|
26 |
C |
p. 257
|
artikel
|
| 52 |
Long-term Reduction in Brain MRI Disease Activity and Atrophy after 5 years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis
|
Arnold, D.L.
|
|
|
26 |
C |
p. 265
|
artikel
|
| 53 |
Long-term Reduction of Relapse Rate and Confirmed Disability progression after 5 years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis
|
Hauser, S.L.
|
|
|
26 |
C |
p. 265-266
|
artikel
|
| 54 |
Low Carbohydrate Diet Score and Neuromyelitis Optica Spectrum Disorder
|
Rezaeimanesh, N.
|
|
|
26 |
C |
p. 245
|
artikel
|
| 55 |
Lymphopenia Rates in Clarity/clarity Extension Are Unrelated to Disease Activity at Baseline
|
Cook, S.
|
|
|
26 |
C |
p. 261
|
artikel
|
| 56 |
Magnetic Resonance Imaging in Multiple Sclerosis (MAGNIMS) Score Predicts Long-term Clinical Disease Activity (CDA)-free Status and Disability Progression in Subcutaneous Interferon Beta-1a (scifnβ-1a)-treated Patients
|
Sormani, M.P.
|
|
|
26 |
C |
p. 240-241
|
artikel
|
| 57 |
Magnetic Resonance Venography Findings in a Group of Patients with Multiple Sclerosis
|
Majeed, A.Q.
|
|
|
26 |
C |
p. 248
|
artikel
|
| 58 |
Micro Ribonucleic Acids (20a, 146a, and 155) and Forkhead Box P3 Genes Expressions in Multiple Sclerosis Patients
|
Aljawadi, Z.A.
|
|
|
26 |
C |
p. 252
|
artikel
|
| 59 |
Modified Functional Walking Categories and participation in people with multiple sclerosis
|
Bertoni, Rita
|
|
|
26 |
C |
p. 11-18
|
artikel
|
| 60 |
Multiple Sclerosis and Autoreactive Antibodies
|
Larnaout, F.
|
|
|
26 |
C |
p. 251
|
artikel
|
| 61 |
Multiple sclerosis and fabry Disease, two sides of the coin? The case of an Italian family
|
Russo, Camilla
|
|
|
26 |
C |
p. 164-167
|
artikel
|
| 62 |
Multiple Sclerosis Burden in Eastern Mediterranean Region from 1990 to 2016
|
Eskandarieh, S.
|
|
|
26 |
C |
p. 244-245
|
artikel
|
| 63 |
Multiple Sclerosis Female to Male Ratio Trend from 1999 to 2017 in Tehran, Iran
|
Eskandarieh, S.
|
|
|
26 |
C |
p. 246-247
|
artikel
|
| 64 |
Multiple Sclerosis in Emirati Population: onset Disease Dissemination by MR Imaging
|
Ahmed, Manzoor
|
|
|
26 |
C |
p. 249
|
artikel
|
| 65 |
Multiple Sclerosis: kFLC index values related to gender
|
Pieri, Massimo
|
|
|
26 |
C |
p. 58-60
|
artikel
|
| 66 |
Multiple Sclerosis Minimum Data Set for National Registry System in Iran: Definition Validity and Reliability
|
Eskandarieh, S.
|
|
|
26 |
C |
p. 246
|
artikel
|
| 67 |
Multiple Sclerosis New Criteria Are Also More Relevant in North Africans
|
Souissi, A.
|
|
|
26 |
C |
p. 239
|
artikel
|
| 68 |
Multiple Sclerosis Treatment Experience in Al-Azhar University Hospitals in Egypt
|
Ali, A.E.
|
|
|
26 |
C |
p. 242
|
artikel
|
| 69 |
Neuromodulation Strategies to Enhance the Effects of Gait Rehabilitation in Multiple Sclerosis Patients with Cerebellar Ataxia Preliminary Data
|
Colnaghi, S.
|
|
|
26 |
C |
p. 266
|
artikel
|
| 70 |
Neuromyelitis Optica Spectrum Disorder and Its Environmental Risk Factors for Nmo-IgG Sero-positivity
|
Eskandarieh, S.
|
|
|
26 |
C |
p. 246
|
artikel
|
| 71 |
Neuromyelitis Optica Spectrum Disorder Presenting with Area Postrema Syndrome: A Case Report
|
Renganathan, R.
|
|
|
26 |
C |
p. 239
|
artikel
|
| 72 |
Neuromyelitis Optica Spectrum Disorders (NMO) Concomitant with Autoimmune Diseases
|
Eskandarieh, S.
|
|
|
26 |
C |
p. 243-244
|
artikel
|
| 73 |
NMOSD with anti-MOG antibodies following anti-TNFα therapy: A case report
|
Lommers, Emilie
|
|
|
26 |
C |
p. 37-39
|
artikel
|
| 74 |
No Evidence of Disease Activity-3 Status Is Durable in Patients with Relapsing Multiple Sclerosis Receiving Cladribine Tablets: Clarity Extension
|
Giovannoni, G.
|
|
|
26 |
C |
p. 259-260
|
artikel
|
| 75 |
No Increase in Malignancy Risk with Cladribine Tablets in Patients with Relapsing Multiple Sclerosis
|
Galazka, A.
|
|
|
26 |
C |
p. 261
|
artikel
|
| 76 |
Novel Assessment of Real-world Effectiveness of Ocrelizumab for Treatment of Patients with Relapsing and Primary Progressive Multiple Sclerosis: Design of a Multicenter Non-interventional Study (musicale Study)
|
Trojano, M.
|
|
|
26 |
C |
p. 256-257
|
artikel
|
| 77 |
Pain in Patients with Multiple Sclerosis (MS)
|
Shabany, M.
|
|
|
26 |
C |
p. 266
|
artikel
|
| 78 |
Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice
|
Coyle, Patricia K.
|
|
|
26 |
C |
p. 211-218
|
artikel
|
| 79 |
Pediatric Multiple Sclerosis Epidemiology in Tehran, Iran
|
Eskandarieh, S.
|
|
|
26 |
C |
p. 242
|
artikel
|
| 80 |
Peginterferon beta-1a for the treatment of relapsing multiple sclerosis: A case series
|
Hendin, Barry A.
|
|
|
26 |
C |
p. 33-36
|
artikel
|
| 81 |
Photophobia in multiple sclerosis
|
Cortese, Antonio
|
|
|
26 |
C |
p. 55-57
|
artikel
|
| 82 |
Pilot investigation of the relationship between hippocampal volume and pattern separation deficits in multiple sclerosis
|
Zuppichini, Mark D.
|
|
|
26 |
C |
p. 157-163
|
artikel
|
| 83 |
Pilot randomized controlled trial of functional electrical stimulation cycling exercise in people with multiple sclerosis with mobility disability
|
Edwards, Thomas
|
|
|
26 |
C |
p. 103-111
|
artikel
|
| 84 |
Pregnancy and Infant Outcomes with Interferon Beta: Data from the European Interferon Beta Pregnancy Registry and Population Based Registries in Finland and Sweden
|
Hellwig, K.
|
|
|
26 |
C |
p. 240
|
artikel
|
| 85 |
Pregnancy Outcomes During the Clinical Development of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety
|
Galazka, A.
|
|
|
26 |
C |
p. 260-261
|
artikel
|
| 86 |
Primary progressive multiple sclerosis in Iran: A consensus recommendation for diagnosis and management
|
Sahraian, Mohammad Ali
|
|
|
26 |
C |
p. 112-120
|
artikel
|
| 87 |
Principles for Planning National MS Registry System and Impact on Patient Care and Health Outcomes
|
Eskandarieh, S.
|
|
|
26 |
C |
p. 247
|
artikel
|
| 88 |
Promising effect of rapamycin on multiple sclerosis
|
Bagherpour, Bahram
|
|
|
26 |
C |
p. 40-45
|
artikel
|
| 89 |
Proton magnetic resonance spectroscopy differentiates tumefactive demyelinating lesions from gliomas
|
Ikeguchi, Ryotaro
|
|
|
26 |
C |
p. 77-84
|
artikel
|
| 90 |
Quantitative Numerical Evaluation of Disability in the Patients with RRMS: Patterns of Neurological Involvement Within 8 Functional SysteMS by Use of an 8-digit Binary Number
|
Dorche, M.S.
|
|
|
26 |
C |
p. 242
|
artikel
|
| 91 |
Radiologically Isolated Syndrome Conversion to Multiple Sclerosis
|
Fateme,
|
|
|
26 |
C |
p. 247-248
|
artikel
|
| 92 |
Rapid Reduction of Lesion Accumulation in Specific White Matter Tracts as Assessed by Lesion Mapping in RRMS Patients Treated with Ifnβ-1a
|
De Stefano, N.
|
|
|
26 |
C |
p. 249
|
artikel
|
| 93 |
Real-world Fingolimod Efficacy and Safety in Emirati Patients with Multiple Sclerosis
|
Ceccarelli, A.
|
|
|
26 |
C |
p. 257-258
|
artikel
|
| 94 |
Real World Retrospective Study of Effectiveness and Safety of Fingolimod in Relapsing Remitting Multiple Sclerosis in the Middle East and North Africa (FINOMENA)
|
Roughani, R. Al
|
|
|
26 |
C |
p. 254
|
artikel
|
| 95 |
Recurrent disseminated encephalomyelitis: A case report and literature review
|
Shah, Suma
|
|
|
26 |
C |
p. 86-89
|
artikel
|
| 96 |
Recurrent schilder's disease
|
Dunn-Pirio, Anastasie M
|
|
|
26 |
C |
p. 8-10
|
artikel
|
| 97 |
Relapse prevalence, symptoms, and health care engagement: patient insights from the Multiple Sclerosis in America 2017 survey
|
Nazareth, Tara A.
|
|
|
26 |
C |
p. 219-234
|
artikel
|
| 98 |
Relationship Between Love of Life and Happiness in Iranian Patients with Multiple Sclerosis
|
Dadfar, M.
|
|
|
26 |
C |
p. 252
|
artikel
|
| 99 |
Reply to correspondence “Cauda equina involvement following dengue fever”
|
Lana-Peixoto, Marco
|
|
|
26 |
C |
p. 85
|
artikel
|
| 100 |
Restless Leg Syndrome in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: A Case-control Study in Iran
|
Barzegar, M.
|
|
|
26 |
C |
p. 253
|
artikel
|
| 101 |
Retrospective analysis of children with myelin oligodendrocyte glycoprotein antibody-related disorders
|
Konuskan, Bahadır
|
|
|
26 |
C |
p. 1-7
|
artikel
|
| 102 |
Risk of Relapses During Pregnancy and Post-partum Period Among Multiple Sclerosis Patients
|
Alroughani, R.
|
|
|
26 |
C |
p. 238
|
artikel
|
| 103 |
Safety liver profile of teriflunomide versus interferon β in multiple sclerosis: Systematic review and indirect comparison meta-analysis
|
Salas, Paola Andrea Ortiz
|
|
|
26 |
C |
p. 192-200
|
artikel
|
| 104 |
Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients with Relapsing and Primary progressive Multiple Sclerosis
|
Hauser, S.L.
|
|
|
26 |
C |
p. 264
|
artikel
|
| 105 |
Season of Birth as a Risk Factor for Multiple Sclerosis in Egypt
|
Zamzam, D.A.
|
|
|
26 |
C |
p. 251
|
artikel
|
| 106 |
Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report
|
Lapucci, C
|
|
|
26 |
C |
p. 52-54
|
artikel
|
| 107 |
Severe disease exacerbation in a patient with neuromyelitis optica spectrum disorder during treatment with dimethyl fumarate
|
Popiel, Malgorzata
|
|
|
26 |
C |
p. 204-206
|
artikel
|
| 108 |
Skin Warts During Fingolimod Treatment in Patients with Multiple Sclerosis
|
Jaafar, N.
|
|
|
26 |
C |
p. 263-264
|
artikel
|
| 109 |
Spinal Cord Lesions Predict Disability Progression in Relapsing Multiple Sclerosis
|
Mrabet, S.
|
|
|
26 |
C |
p. 238-239
|
artikel
|
| 110 |
Static postural control disturbances among the different multiple sclerosis phenotypes: A Neurocom Balance Manager® evaluation study
|
Cimino, V.
|
|
|
26 |
C |
p. 46-51
|
artikel
|
| 111 |
Stress-full life events and multiple sclerosis: A population-based incident case-control study
|
Abdollahpour, Ibrahim
|
|
|
26 |
C |
p. 168-172
|
artikel
|
| 112 |
Successful treatment of paraneoplastic longitudinally extensive transverse myelitis (LETM): A 16-month clinical-spinal MRI follow-up
|
Ivanovic, Jovana
|
|
|
26 |
C |
p. 207-210
|
artikel
|
| 113 |
Sustained Reduction in Confirmed Disability Progression in Patients with Primary Progressive Multiple Sclerosis Treated with Ocrelizumab in the Open-label Extension Period of the Phase III ORATORIO trial
|
Hauser, S.L.
|
|
|
26 |
C |
p. 264-265
|
artikel
|
| 114 |
The Bayesian risk estimate at onset (BREMSO) correlates with cognitive and physical disability in patients with early multiple sclerosis
|
Said, Marianne
|
|
|
26 |
C |
p. 96-102
|
artikel
|
| 115 |
The dilemma of benign multiple sclerosis: Can we predict the risk of losing the “benign status”? A 12-year follow-up study
|
Razzolini, Lorenzo
|
|
|
26 |
C |
p. 71-73
|
artikel
|
| 116 |
The Patterns of Clinical Presentation of Multiple Sclerosis in Patients Admitted to the National Center of Neurological Sciences, Khartoum, Sudan 2018
|
Ibrahim, E.A.A.
|
|
|
26 |
C |
p. 238
|
artikel
|
| 117 |
Toll Like Receptors 2 and 4 Expression in Peripheral Blood Lymphocytes and Neutrophils of Egyptian Multiple Sclerosis Patients: A Case Control Study
|
Elmazny, A.
|
|
|
26 |
C |
p. 243
|
artikel
|
| 118 |
Tumefactive Demyelinating Lesion in a Patient Taking Fingolimod: A Case Report from the UAE
|
Pires, M.C.C.
|
|
|
26 |
C |
p. 237
|
artikel
|
| 119 |
Tumefactive Multiple Sclerosis: Emerging Role of MR Spectroscopy
|
Siddiqi, S.A.
|
|
|
26 |
C |
p. 248
|
artikel
|
| 120 |
Updated Safety Analysis of Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis
|
Cook, S.
|
|
|
26 |
C |
p. 260
|
artikel
|
| 121 |
Vaccines and disease-modifying treatments
|
Waubant, Emmanuelle
|
|
|
26 |
C |
p. A1-A2
|
artikel
|
| 122 |
Various Types of Dietary Sugar and Neuromyelitis Optica Spectrum Disorder
|
Rezaeimanesh, N.
|
|
|
26 |
C |
p. 244
|
artikel
|
Tijdschrift beschrijving